VF
VIRX

Virtu Financial’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Virtu Financial’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-128,231
Closed -$21K – 2225
2024
Q4 		$21K Buy
+128,231
New +$25.2K ﹤0.01% 1296
2024
Q3 		– Sell
-30,789
Closed -$17K – 2012
2024
Q2 		$17K Buy
+30,789
New +$24.3K ﹤0.01% 1057
2024
Q1 		– Sell
-27,378
Closed -$16K – 2254
2023
Q4 		$16K Buy
+27,378
New +$16.8K ﹤0.01% 1356
2023
Q1 		– Sell
-19,568
Closed -$29K – 2221
2022
Q4 		$29K Buy
+19,568
New +$57.1K ﹤0.01% 1191
2020
Q3 		– Sell
-2,533
Closed -$23K – 1620
2020
Q2 		$23K Buy
+2,533
New +$38.2K ﹤0.01% 1122
2019
Q4 		– Sell
-1,036
Closed -$26K – 1936
2019
Q3 		$26K Buy
1,036
+374
+56% +$10.8K ﹤0.01% 1265
2019
Q2 		$17K Buy
+662
New +$25.6K ﹤0.01% 1360
2018
Q2 		– Sell
-1,060
Closed -$101K – 2595
2018
Q1 		$101K Buy
+1,060
New +$182K 0.01% 1575
2017
Q4 		– Sell
-288
Closed -$20K – 3129
2017
Q3 		$20K Buy
+288
New +$23.5K ﹤0.01% 2353

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Virtu Financial's VIRX Position: Q1 2025 in Review

Virtu Financial sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 128,231 shares — an estimated $21K sold.

Virtu Financial first reported a position in VIRX in Q3 2017 and held it in 9 quarters. The position peaked at $101K in Q1 2018. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Virtu Financial reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Virtu Financial sold 128,231 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $21K.
  • Virtu Financial first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2017 and held it in 9 quarters.
  • Virtu Financial's Viracta Therapeutics, Inc. Common Stock position peaked at $101K in Q1 2018.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Virtu Financial's 13F filing for Q1 2025, filed 12 May 2025.